NEW YORK (GenomeWeb News) - Sequenom said after the close of the market yesterday that it has agreed to issue additional shares to shareholders of SensiGen to settle certain claims asserted following Sequenom's purchase of SensiGen's assets.

According to a filing with the US Securities and Exchange Commission, Sequenom will issue to certain stockholders 367,547 shares of its common stock. In July, those shareholders had asserted claims for damages of around $1.3 million from an alleged breach of representations and warranties made by Sequenom in its asset purchase agreement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: self-assembly of DNA components in solution, and more.

Genetics and Molecular Research retracts two gastric cancer papers for being "substantially equal" to other papers, according to Retraction Watch.

A new analysis indicates that the Ebola virus behind the current West African outbreak is mutating at about the same rate as other Ebola viruses.

With the launch of Scott Kelly into space today, the study of him and his earthbound brother to disentangle the effects of life in space from the effects of genetics kicks off.